Cost-utility analysis of a ‘vonoprazan-first’ strategy versus ‘esomeprazole- or rabeprazole-first’ strategy in GERD

ConclusionsVonoprazan-first strategy increased QALYs and appeared to be cost-effective for GERD patients compared with the esomeprazole- or rabeprazole-first strategies.

http://link.springer.com/10.1007/s00535-019-01609-2

Source: Journal of Gastroenterology - August 7, 2019 Category: Gastroenterology Source Type: research